Vivactil and Surmontil, both tricyclic antidepressants frequently prescribed for anxiety disorders, exhibit distinct pharmacological profiles. Vivactil (nortriptyline), known for its potent inhibitory effects on serotonin and norepinephrine reuptake, reveals a higher affinity for alpha-2 adrenergic receptors. This alters its potential for sedative